公开(公告)号：US5439679A

公开(公告)日：1995-08-08

申请号：US208202

申请日：1994-03-10

申请人： Ernest-Guenter Afting ,  Eric-Paul Paques ,  Nancy L. Haigwood ,  Guy Mullenbach

发明人： Ernest-Guenter Afting ,  Eric-Paul Paques ,  Nancy L. Haigwood ,  Guy Mullenbach

IPC分类号： C12N9/64 ,  A61K38/00 ,  A61K38/46 ,  A61K38/48 ,  A61P7/02 ,  C07H21/04 ,  C07K14/745 ,  C12N5/00 ,  C12N5/10 ,  C12N9/72 ,  C12N15/00 ,  C12N15/09 ,  C12N15/10 ,  C12N15/55 ,  C12N15/58 ,  C12P21/00 ,  C12R1/91 ,  C12N9/48

CPC分类号： C12N9/6459 ,  C12N15/10 ,  C12Y304/21069

摘要： Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.The plasmids designated 1, 2 and 3 were deposited at the A.T.C.C. on Dec. 20, 1985 and given A.T.C.C. designations 40214, 40215 and 40216, respectively.

摘要翻译： 提供基于组织纤溶酶原激活物（tPA）的氨基酸序列的新型多肽组合物，其具有比天然组织纤溶酶原激活物更好的性质。 特别地，通过用缺失或取代修饰一个或多个基因座来提供增强的比活性，对纤维蛋白溶酶原激活物抑制剂抑制的反应降低，纤维蛋白溶解活性的纤维蛋白刺激和/或对纤维蛋白表面的增强的亲和力。 N-或C-末端中的一个或两个可以被修饰。 指定为1,2和3的质粒在A.T.C.C. 1985年12月20日和A.T.C.C. 名称40214,40215和40216。

公开(公告)号：US5501853A

公开(公告)日：1996-03-26

申请号：US944117

申请日：1986-12-22

申请人： Nancy L. Haigwood ,  Ernest-Guenter Afting ,  Guy Mullenbach ,  Eric P. Paques

发明人： Nancy L. Haigwood ,  Ernest-Guenter Afting ,  Guy Mullenbach ,  Eric P. Paques

IPC分类号： C12N9/64 ,  A61K38/00 ,  A61K38/46 ,  A61K38/48 ,  A61P7/02 ,  C07H21/04 ,  C07K14/745 ,  C12N5/00 ,  C12N5/10 ,  C12N9/72 ,  C12N15/00 ,  C12N15/09 ,  C12N15/10 ,  C12N15/55 ,  C12N15/58 ,  C12P21/00 ,  C12R1/91 ,  A61K38/49

CPC分类号： C12N9/6459 ,  C12N15/10 ,  C12Y304/21069

摘要： Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.